Surgical throughput, drug cost, and an optical shop on the side.
Ophthalmology combines a high-throughput surgical business, a drug-heavy retina and injection line, and often an optical dispensary. Each moves on different economics, and blended reporting hides all three. The monthly briefing reads surgical volume and site of service, injection and buy-and-bill margin, clinic access, and retail contribution as separate lines.
Where the specialty stands
Ophthalmology continues its long migration to ASCs and office-based procedure suites, with cataract still the volume engine and retina still the drug-spend engine. Premium IOLs, refractive cash channels, and disciplined ASC utilization are where well-run groups create real margin separation.
- ASC ownership and office-based surgery suites (intravitreal injections, YAG, MIGS in some states) keep moving cases out of HOPDs.
- Premium IOL conversion and refractive cash-pay channels remain the highest-leverage revenue lines for cataract-heavy groups.
- Retina drug economics (Eylea biosimilars, Vabysmo, faricimab dynamics) are reshaping the buy-and-bill side of the practice.
- PE consolidation continues; choices about platform partnership, MD/OD integration, and governance get more consequential each year.
- MIGS, gene therapy for retinal disease, and AI screening for diabetic retinopathy are the long-arc clinical/operational stories.
What the briefing reads for a ophthalmology practice
Cataract and other case volume, block utilization, and turnover. Small changes in cases per block move practice income more than almost anything else on the schedule.
Patient-pay upgrades and elective work tracked apart from covered procedures, including conversion rate at the counseling step.
Acquisition cost, payer payment, and the lag between the two for buy-and-bill drugs. A payment delay on high-cost inventory is a working capital problem before it is a margin problem.
Workup time, technician ratio, and provider touch time. Clinic throughput is usually constrained by technician capacity, not physician capacity.
Dispensary capture, testing revenue, and their contribution after direct cost.
Illustrative reference ranges
Read the methodologyThese internally authored, industry-informed estimates provide specialty context. They are not live peer data, licensed survey medians, targets, or promises.
| Indicator | Lower reference | Central reference | Upper reference |
|---|---|---|---|
| Revenue per provider (monthly) | $85k | $110k | $135k |
| Average reimbursement rate | 62% | 70% | 78% |
| Contractual adjustment rate | 24% | 30% | 36% |
| Scheduling efficiency | 75% | 82% | 89% |
| Days in A/R | 28 days | 36 days | 44 days |
| Operating expense ratio | 56% | 62% | 68% |
| Net collection rate | 93.5% | 96% | 97.8% |
| Commercial payer mix | 48% | 60% | 72% |
| Third next available appointment | 7 days | 12 days | 18 days |
| No-show rate | 4.5% | 6.5% | 9% |
| Staff per provider | 2.8 | 3.4 | 4 |
| Provider turnover | 4% | 7% | 11% |
| Training investment (% of payroll) | 1.2% | 2% | 2.8% |
| Cost per visit | $180 | $220 | $270 |
| Patient satisfaction | 4.2 / 5 | 4.5 / 5 | 4.7 / 5 |
| Quality compliance rate | 87% | 92% | 96% |
Questions this briefing is built to answer
- Is block time producing the case volume we are paying for?
- What is our premium conversion rate, and where do patients drop out?
- Are drug payments keeping pace with acquisition cost and timing?
- Is technician staffing the real constraint on clinic volume?
- Which site of service is producing the best economics for our cases?
- How much does the optical shop contribute after its own costs?
What we read to stay current
See what this looks like for your practice
Send aggregate practice data for a recent period and we will show you the executive brief format: what changed, why it may matter, likely drivers, and what to watch.
AileronMD analyzes business, financial, and operational data only. Do not submit patient records or protected health information. AileronMD does not provide clinical or medical advice, and does not guarantee financial results. Guidance is advisory; practice leadership makes the decisions.